Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.75 |
| ▸ | ABL1 | P00519 | 11/20 | 0.73 |
| ▸ | ROR1 | Q01973 | 6/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.67 |
| ▸ | KIT | P10721 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.62 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.62 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.62 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.62 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.62 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.62 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19317721 | 0.92 | ROR1 (0.79) | CSF1RABL1ROR1CYP3A4KCNH2 | |
| SCHEMBL16644461 | 0.88 | ABL1 (0.84) | CSF1RABL1ROR1CYP3A4KCNH2 | |
| SCHEMBL22559533 | 0.87 | ABL1 (0.78) | CSF1RABL1ROR1CYP3A4KCNH2 | |
| SCHEMBL22559451 | 0.87 | CSF1R (0.70) | CSF1RABL1ROR1CYP3A4KCNH2 | |
| SCHEMBL22559443 | 0.87 | ABL1 (0.78) | CSF1RABL1ROR1CYP3A4KCNH2 | |
| SCHEMBL16250614 | 0.86 | ABL1 (0.80) | CSF1RABL1ROR1CYP3A4KCNH2 | |
| SCHEMBL30987915 | 0.86 | ROR1 (0.75) | CSF1RABL1ROR1CYP3A4KCNH2 | |
| SCHEMBL24122640 | 0.85 | ABL1 (1.00) | CSF1RABL1ROR1CYP3A4KCNH2 | |
| SCHEMBL30011304 | 0.85 | ABL1 (1.00) | CSF1RABL1ROR1CYP3A4KCNH2 | |
| SCHEMBL12682241 | 0.85 | ROR1 (0.72) | CSF1RABL1ROR1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | CSF1R 2599/4885ABL1 75/4885ROR1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.